MedKoo Cat#: 526528 | Name: UK 66914

Description:

WARNING: This product is for research use only, not for human or veterinary use.

UK 66914 is a K(+)-channel blocker.

Chemical Structure

UK 66914
UK 66914
CAS#113049-11-9

Theoretical Analysis

MedKoo Cat#: 526528

Name: UK 66914

CAS#: 113049-11-9

Chemical Formula: C18H24N4O3S

Exact Mass: 376.1569

Molecular Weight: 376.48

Elemental Analysis: C, 57.43; H, 6.43; N, 14.88; O, 12.75; S, 8.52

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
UK 66914, UK-66914, UK66914
IUPAC/Chemical Name
Methanesulfonamide, N-(4-(1-hydroxy-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl)phenyl)-
InChi Key
MXVFGNOLZDAKQJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H24N4O3S/c1-26(24,25)20-16-4-2-15(3-5-16)18(23)14-21-10-12-22(13-11-21)17-6-8-19-9-7-17/h2-9,18,20,23H,10-14H2,1H3
SMILES Code
CS(=O)(NC1=CC=C(C(O)CN2CCN(C3=CC=NC=C3)CC2)C=C1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 376.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Rees SA, Vandenberg JI, Wright AR, Yoshida A, Powell T. Cell swelling has differential effects on the rapid and slow components of delayed rectifier potassium current in guinea pig cardiac myocytes. J Gen Physiol. 1995 Dec;106(6):1151-70. PubMed PMID: 8786354; PubMed Central PMCID: PMC2229303. 2: MacKenzie I, Saville VL, Waterfall JF. Differential class III and glibenclamide effects on action potential duration in guinea-pig papillary muscle during normoxia and hypoxia/ischaemia. Br J Pharmacol. 1993 Oct;110(2):531-8. PubMed PMID: 8242227; PubMed Central PMCID: PMC2175944. 3: Tweedie D, Henderson C, Kane K. Glibenclamide, but not class III drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts. Eur J Pharmacol. 1993 Aug 24;240(2-3):251-7. PubMed PMID: 8243542. 4: Gwilt M, Orme J, Rourke JD, Henderson CG. K(+)-channel blockers and coronary vasoconstriction in guinea-pig perfused hearts in-vitro. J Pharm Pharmacol. 1993 Jul;45(7):671-4. PubMed PMID: 8105068. 5: Rees SA, Curtis MJ. Selective IK blockade as an antiarrhythmic mechanism: effects of UK66,914 on ischaemia and reperfusion arrhythmias in rat and rabbit hearts. Br J Pharmacol. 1993 Jan;108(1):139-45. PubMed PMID: 8428204; PubMed Central PMCID: PMC1907696. 6: Gwilt M, Henderson CG, Orme J, Rourke JD. Effects of drugs on ventricular fibrillation and ischaemic K+ loss in a model of ischaemia in perfused guinea-pig hearts in vitro. Eur J Pharmacol. 1992 Sep 22;220(2-3):231-6. PubMed PMID: 1425994. 7: Wallace AA, Stupienski RF 3rd, Brookes LM, Selnick HG, Claremon DA, Lynch JJ Jr. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs. J Cardiovasc Pharmacol. 1991 Nov;18(5):687-95. PubMed PMID: 1723765. 8: Baskin EP, Serik CM, Wallace AA, Brookes LM, Selnick HG, Claremon DA, Lynch JJ Jr. Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle. J Cardiovasc Pharmacol. 1991 Sep;18(3):406-14. PubMed PMID: 1720841. 9: Gwilt M, Dalrymple HW, Burges RA, Blackburn KJ, Dickinson RP, Cross PE, Higgins AJ. Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol. 1991 Mar;17(3):376-85. PubMed PMID: 1711597.